the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
October 24, 2015 – The Amrican Food and Drug Administration approved Trabectedin (Yondelis) for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. The approval of trabectedin is based on improvement in progression-free survival (PFS) in a multicenter, …
October 11, 2015 – In recent months, Nivolumab (Opdivo), a human IgG4 anti-PD-1 monoclonal antibody which targets the PD-1 receptor, had been approved first for the treatment of unresectable or advanced (metastatic) melanoma and secondly for the treatment of advanced (metastatic) squamous non-small cell …
October 06, 2015 – Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. Among lung cancers, non-small cell lung …
October 02, 2015 – Recently, the American Food and Drug Administration (FDA) approved Sacubitril/Valsartan (Entresto) for the treatment of heart failure. Similarly, a few days ago, the European Medicines Agency (EMA) recommended granting a marketing authorisation for Sacubitril/Valsartan (Entresto) for the treatment of adults with symptomatic chronic heart failure …
September 19, 2015 – The American Food and Drug Administration (FDA) just approved Cariprazine (Vraylar) capsules to treat schizophrenia and bipolar disorder in adults. Schizophrenia is a chronic, severe and disabling brain disorder affecting about one percent of Americans. Typically, …
Cariprazine (Vraylar): New treatment for schizophrenia and bipolar disorder approved Read more »
September 12, 2015 – Drug Safety Information: The American Food and Drug Administration (FDA) has just strengthened the warning for the type 2 diabetes medicines containing canagliflozin as active ingredient, i.e. Invokana and Invokamet, related to the increased risk of bone …
September 2, 2015 – The U.S. Food and Drug Administration approved Rodapitant (Varubi) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Rodapitant (Varubi) is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated …
2. September 2015 – Die Amerikanische Food and Drug Administration (FDA) hat eben Rodapitant (Varubi) zugelassen. Rodapitant (Varubi)um soll Chemotherapie-induzierte Übelkeit und Erbrechen (Emesis) verhindern. Rodapitant (Varubi) wird bei Erwachsenen in Kombination mit anderen Arzneimitteln (Brechreizhemmenden Agentien) eingesetzt um die Übelkeit …
September 06, 2015 – The American Food and Drug Administration just approved Uridine Triacetate (Xuriden), the first FDA-approved treatment for patients with hereditary orotic aciduria. Hereditary orotic aciduria is a rare metabolic disorder, which has been reported in approximately 20 …
September 01, 2015 – The American Food and Drug Administration recently approved Evolocumab (Repatha) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. Evolocumab (Repatha), the second drug approved in a …
Evolocumab (Repatha) to treat certain patients with high cholesterol Read more »